Acasti Pharma Inc. (ACST)
NASDAQ: ACST
· Real-Time Price · USD
3.37
0.13 (4.01%)
At close: Oct 25, 2024, 10:00 PM
Acasti Pharma Income Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
Revenue | 4.83M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -32K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 4.83M | n/a | 4.83M | 1K | 1K | 3.04M | 2.09M | 4.45M | 14.08M | 4.25M | 5.11M | 4.73M | 12.02M | 4.47M | 3.57M | n/a |
Gross Profit | 1K | n/a | -4.83M | -1K | -1K | -3.04M | -2.09M | -4.45M | -14.12M | -4.25M | -5.11M | -4.73M | -12.02M | n/a | -3.57M | n/a |
Operating Income | 9.79M | n/a | -4.83M | -4.96M | -4.34M | -4.03M | -2.84M | -4.45M | -5.62M | -5.75M | -5.11M | -6.09M | -1.5M | -4.47M | -3.57M | -3.15M |
Interest Income | -407K | n/a | 172K | 235K | 249K | 418.69K | 287.95K | 177.51K | 187K | 67K | 49.72K | 32K | 66K | 40K | 14K | 139K |
Pretax Income | -382K | -4.76M | -4.28M | -3.34M | -4.05M | -2.6M | -3.72M | -4.31M | -51.3M | -4.16M | -5.08M | -4.77M | -4.55M | -3.78M | 981K | -3.12M |
Net Income | -1.96M | -4.76M | -3.43M | -2.62M | -3.17M | -2.39M | -3.27M | -4.02M | -29.09M | -3.89M | -4.93M | -4.52M | -3.9M | -3.78M | 981K | -3.12M |
Selling & General & Admin | 1.55M | 1.51M | 1.85M | 2.25M | 1.54M | 1.6M | 2.22M | 1.65M | 2.52M | 1.77M | 1.83M | 2.09M | 2.08M | 2.05M | 2.93M | 2.68M |
Research & Development | 1.63M | 2.19M | 2.98M | 2.71M | 1.69M | 1.44M | 460K | 1.09M | 1.64M | 2.45M | 3.29M | 2.59M | 2.33M | 2.18M | 585K | 469K |
Other Expenses | -3K | n/a | 2K | 1K | 35K | n/a | 1K | 1.49M | -175K | 20K | -12K | 46K | n/a | 249K | n/a | n/a |
Operating Expenses | 3.18M | 3.7M | 4.83M | 4.96M | 3.26M | 3.04M | 2.01M | 4.45M | 4.17M | 4.25M | 5.11M | 4.73M | 4.4M | 4.22M | 1.23M | 3.15M |
Interest Expense | -235K | n/a | n/a | 235K | n/a | 316K | 212K | 134K | 19K | n/a | 36K | n/a | 33K | n/a | n/a | 139K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 61K | 30K | 58.4K | 60K | 51K | 72K | 3K | 10K | 255K | -238K | -25K | n/a |
Cost & Expenses | 8.02M | n/a | 4.83M | 4.96M | 3.26M | 3.86M | 4.1M | 5.89M | 4.17M | 5.73M | 5.11M | 6.18M | 5.55M | 4.83M | 3.57M | 3.15M |
Income Tax Expense | 1.58M | n/a | -852K | -724K | -889K | -208K | -446K | -289K | -8.87M | -274K | -155K | -242K | -532K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 12.09M | 11.51M | 11.51M | 10.93M | 9.4M | 7.44M | 7.55M | 7.44M | 7.43M | 7.43M | 7.42M | 7.39M | 7.38M | 7.38M | 5.46M | 4.34M |
Shares Outstanding (Diluted) | 12.09M | 11.51M | 11.51M | 10.93M | 9.4M | 7.44M | 7.55M | 7.44M | 7.43M | 7.43M | 7.42M | 7.39M | 7.38M | 7.38M | 5.46M | 4.34M |
EPS (Basic) | 0.11 | -0.36 | -0.3 | -0.24 | -0.34 | -0.32 | -0.43 | -0.54 | -3.91 | -0.52 | -0.66 | -0.61 | -0.54 | -0.51 | 0.18 | -0.72 |
EPS (Diluted) | 0.11 | -0.36 | -0.3 | -0.24 | -0.34 | -0.32 | -0.43 | -0.54 | -3.91 | -0.52 | -0.66 | -0.61 | -0.54 | -0.51 | 0.18 | -0.72 |
EBITDA | -620K | n/a | -4.83M | -4.96M | -3.23M | -3.04M | -2.09M | -3.91M | -4.16M | -4.22M | -5.12M | -4.56M | -4.4M | -4.22M | -3.57M | -3.15M |
EBIT | 9.79M | n/a | -4.83M | -4.96M | -3.26M | -3.04M | -2.09M | -2.97M | -4.17M | -4.25M | -5.11M | -4.73M | -4.4M | -4.22M | -3.57M | -3.15M |
Depreciation & Amortization | -3K | n/a | 2K | 1K | 1K | 1K | 2K | 7K | 8K | 10K | -61K | 167K | 182K | -158K | 292.63K | 112K |